Abstract:Key PointsSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase that has long been thought to exclusively mediate signalling by receptors of the adaptive immune response (B cell receptors (BCRs) and Fc receptors (FcRs)). However, recent studies indicate that it also participates in innate immunity and non-immune functions.SYK activation proceeds through binding of its two SRC homology 2 (SH2) domains to phosphorylated tyrosine residues in immunoreceptor tyrosine-based activation motifs (ITAMs) or ITAM-like sequences in C-type lectins. Binding to phosphorylated ITAMs relieves SYK from an intramolecular autoinhibition and triggers its association with receptor-proximal signalling molecules.SYK mediates integrin signalling in neutrophils, macrophages and platelets, signalling by P-selectin glycoprotein ligand 1 (PSGL1), as well as the development of osteoclasts. These responses are mediated by ITAM-containing adaptor molecules (mostly DAP12 and FcRγ).SYK participates in innate recognition of fungal and other microbial pathogens, as well as of tissue damage, by C-type lectins. SYK activation by C-type lectins activates the caspase-recruitment domain 9–B cell lymphoma 10–mucosa-associated lymphoid tissue lymphoma translocation protein 1 (CARD9–BCL-10–MALT1) pathway and it is also required for NLR family, pyrin domain-containing 3 (NLRP3) inflammasome activation following fungal infection.The phosphorylated ITAM-mediated activation of the SYK homologue SH2 domain ankyrin repeat kinase (SHARK) is required to remove cellular debris in Drosophila melanogaster. This finding indicates an ancient origin of the ITAM–SYK signalling pathway.SYK is required for the separation of newly formed lymphatic vessels from the blood vasculature. This function is probably mediated by the SYK-coupled receptor CLEC2 in platelets.SYK has a central role in the development of allergic and autoimmune diseases, as well as in haematological malignancies such as B cell lymphomas. A new SYK inhibitor has shown beneficial effects in human rheumatoid arthritis and B cell lymphomas.

New insights into SYK targeting in solid tumors

Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents

Systematic analysis of spleen tyrosine kinase expression and its clinical outcomes in various cancers

The ubiquitous role of spleen tyrosine kinase (Syk) in gut diseases: From mucosal immunity to targeted therapy

The SYK tyrosine kinase: a crucial player in diverse biological functions

Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull's eye for targeted therapy?

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells.

Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia

Abstract 3246: Targeting Syk reprograms tumor-associated macrophages and enhances responses to immune checkpoint blockade and radiation therapy in high-risk neuroblastoma

Development of SYK NanoBRET Cellular Target Engagement Assays for Gain–of–Function Variants

SYK regulates mTOR signaling in AML

TYK2: An Upstream Kinase of STATs in Cancer

Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far